Skip to main content
. 2020 Feb 26;10(2):e034388. doi: 10.1136/bmjopen-2019-034388

Table 3.

One-way sensitivity analyses* of model parameters (mean per 100 000 persons) by strategy

Costs (£ millions) Quality-adjusted life years Primary prevention versus early detection Primary prevention versus no intvn
Early detection Primary prevention No intvn Early detection Primary prevention No intvn Incremental cost (£m) Incremental QALYs Incremental cost (£m) Incremental QALYs
Base case (30 years duration, age 50, 3% discounting costs and QALYs) 493.5 386.4 406.1 1 821 195 1 822 937 1 821 201 107.1 1742 19.7 1736
Cost of wbCSE in high users(base AU$112.80)
Cost of wbCSE in high users=$55.58 441.3 386.4 406.1 1 821 195 1 822 937 1 821 201 −54.9 1742 −19.7 1736
Cost of wbCSE in high users=$169.20 545.4 386.4 406.1 1 821 195 1 822 937 1 821 201 −159.0 1742 −19.7 1736
Prob thick melanoma (base 0.25)
Prob thick melanoma=0.21 488.2 386.4 406.1 1 821 686 1 822 937 1 821 201 −101.8 1251 −19.7 1736
Prob thick melanoma=0.29 497.7 386.4 406.1 1 820 811 1 822 937 1 821 201 −111.3 2126 −19.7 1736
Rate reduction in benign lesions from sunscreen (base 0.76)
RR 0.66 493.5 381.1 406.1 1 821 195 1 822 822 1 821 201 −112.4 1627 −25.1 1621
RR 0.86 493.5 392.1 406.1 1 821 195 1 823 055 1 821 201 −101.5 1860 −14.0 1854
KC utility (base 0.98)
Utility 0.95 493.5 386.4 406.1 1 819 784 1 821 928 1 819 831 −107.1 2145 −19.8 2097
Utility 0.99 493.5 386.4 406.1 1 821 408 1 823 086 1 821 408 −107.1 1677 −19.8 1677
Rate reduction in melanoma from sunscreen (base 0.50)
RR 0.45 493.5 384.2 406.1 1 821 195 1 823 158 1 821 201 −109.3 1963 −21.9 1957
RR 0.55 493.5 388.5 406.1 1 821 195 1 822 720 1 821 201 −105.0 1525 −17.6 1519
Mortality prob of thick 5  years: 0.233; 10  years: 0.301
Prob 0.27 to 0.34 494.3 386.8 407.0 1 821 065 1 822 867 1 821 069 −107.5 1802 20.1 1799
Prob 0.19 to 0.26 492.4 385.8 405.0 1 821 376 1 823 035 1 821 387 −106.6 1659 19.2 1648

Bold values are the main analysis results to compare with the other sensitivity analyses result.

*Analyses were performed by changing the parameter of interest and rerunning the model with 5000 Monte Carlo simulations.

KC, keratinocyte cancers; QALYs, quality-adjusted life years; RR, relative risk; wbCSE, whole-body clinical skin examination.